Canadian Cancer Trials Group Bulletins

General


Recent Publications

BR.10 -- A Phase III Prospective Randomized Study of Adjuvant Chemotherapy with Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer with Companion Tumour Marker Evaluation

Jang RW, Le Maître A, Ding K, Winton T, Bezjak A, Seymour L, Shepherd FA, Leighl NB. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: An analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial (ONLINE). J Clin Oncol 2009.
http://jco.ascopubs.org/cgi/content/abstract/JCO.2008.20.5815v1

IND.163 -- A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients with Recurrent/Metastatic Breast Cancer

Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: Canadian Cancer Trials Group IND.163. (ONLINE). J Clin Oncol 2009.
http://jco.ascopubs.org/cgi/content/abstract/JCO.2008.21.3033v1


PR.8 -- Phase III Study of Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer

Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, DiPaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group trials 9346 (Intergroup Study 0162) and 9916. Journal of Clinical Oncology 27(15): 2450-2456, 2009.
http://jco.ascopubs.org/cgi/content/full/27/15/2450